0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessFamilial hyperaldosteronism type II (FH-II) is characterized by autosomal dominant inheritance and hypersecretion of aldosterone due to adrenocortical hyperplasia or an aldosterone-producing adenoma; unlike FH type I (FH-I), hyperaldosteronism in FH-II is not suppressible by dexamethasone. Of a total of 17 FH-II families with 44 affected members, we studied a large kindred with 7 affected members that was informative for linkage analysis. Family members were screened with the aldosterone/PRA ratio test; patients with aldosterone/PRA ratio greater than 25 underwent fludrocortisone/salt suppression testing for confirmation of autonomous aldosterone secretion. Postural testing, adrenal gland imaging, and adrenal venous sampling were also performed. Individuals affected by FH-II demonstrated lack of suppression of plasma A levels after 4 days of dexamethasone treatment (0.5 mg every 6 h). All patients had negative genetic testing for the defect associated with FH-I, the CYP11B1/CYP11B2 hybrid gene. Genetic linkage was then examined between FH-II and aldosterone synthase (the CYP11B2 gene) on chromosome 8q. A polyadenylase repeat within the 5′-region of the CYP11B2 gene and 9 other markers covering an approximately 80-centimorgan area on chromosome 8q21–8qtel were genotyped and analyzed for linkage. Two-point logarithm of odds scores were negative and ranged from −12.6 for the CYP11B2 polymorphic marker to −0.98 for the D8S527 marker at a recombination distance (θ) of 0. Multipoint logarithm of odds score analysis confirmed the exclusion of the chromosome 8q21–8qtel area as a region harboring the candidate gene for FH-II in this family. We conclude that FH-II shares autosomal dominant inheritance and hyperaldosteronism with FH-I, but, as demonstrated by the large kindred investigated in this report, it is clinically and genetically distinct. Linkage analysis demonstrated that the CYP11B2 gene is not responsible for FH-II in this family; furthermore, chromosome 8q21–8qtel most likely does not harbor the genetic defect in this kindred.
David J. Torpy, Richard D. Gordon, Jing Lin, Phillip R. Huggard, Susan E. Taymans, Michael Stowasser, George Chrousos, Constantine A. Stratakis (1998). Familial Hyperaldosteronism Type II: Description of a Large Kindred and Exclusion of the Aldosterone Synthase (CYP11B2) Gene<sup>1</sup>. , 83(9), DOI: https://doi.org/10.1210/jcem.83.9.5086.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
1998
Authors
8
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1210/jcem.83.9.5086
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access